Overview
Ready-to-use stabilized CRE mRNA.
Concentration: 1.0 mg/mL in 1 mM Sodium Citrate, pH 6.4.
CRE mRNA has been designed to produce high expression level of CRE recombinase fused to a nuclear localization sequence (NLS).
OZ Biosciences mRNAs are produced by in vitro transcription and stabilized at the 5’ end by modified nucleotides capping (Cap1). These mature mRNAs contain a poly(A) tail at the 3’ end and are also optimized to yield improved stability and performance.
CRE mRNAs:
-
#MRNA33 does not bear any additional nucleotide modifications.
-
#MRNA32 is modified with 5-methoxyuridine (5moU) to reduce innate immune responses.
-
#MRNA26 is modified with N1-methyl-pseudouridine (N1-mψ) to reduce innate immune response.
Size: 20 µg or 100µg
Storage: -80°C
mRNAs ARE SHIPPED WITH DRY ICE
CATALOG NUMBER |
UNIT SIZE |
MRNA33-20 |
CRE mRNA Unmodified 20 µg
|
MRNA33-100 |
CRE mRNA Unmodified 100 µg
|
MRNA33-1000 |
CRE mRNA Unmodified 1 mg
|
MRNA32-20 |
CRE mRNA (5moU) 20 µg
|
MRNA32-100 |
CRE mRNA (5moU) 100 µg
|
MRNA32-1000 |
CRE mRNA (5moU) 1 mg
|
MRNA26-20 |
CRE mRNA (N1-mψ) 20 µg
|
MRNA26-100 |
CRE mRNA (N1-mψ) 100 µg
|
MRNA26-1000 |
CRE mRNA (N1-mψ) 1 mg
|
Applications
CRE mRNA encodes for the CRE Recombinase is a Type I topoisomerase from bacteriophage P1 that catalyzes the site-specific recombination of DNA between two loxP sites.